Please login to read the full article.
Scrip Regulatory Affairs
EU medtech regulatory reform could involve unannounced notified body visits, greater transparency and tighter controls on Class III devices
08 February 2012
Amanda Maxwell
Please login to read the full article.
Not a subscriber ? Request a FREE Trial
Subscribe to Regulatory Affairs Pharma
RELATED CONTENT
NEWS
Scrip Regulatory Affairs News
- Eucomed calls for stricter regulatory control for medtech and pinpoints where it is needed
- April brings in new French healthcare laws: update on the implementing rules
- Proposed new feature in future EU IVD Regulation: the classification rules
- EU medtech regulators' group sticks to legally correct labelling decision, launches transparency initiative
Other Informa News
ANALYSIS
Regulatory Affairs Pharma Analysis
Other Informa Analysis
EDITORIALS
Regulatory Affairs Pharma Editorials
Other Informa Editorials
FEATURES
Regulatory Affairs Pharma Features
Other Informa Features
COMMENT
Regulatory Affairs Pharma Comment
Other Informa Comments
